Latest Conference Articles

September 11th 2021, 5:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

September 11th 2021, 5:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

September 11th 2021, 3:47pm

IASLC World Conference on Lung Cancer

Frontline sequential therapy with crizotinib followed by alectinib demonstrated survival benefits for patients with ALK-positive non–small cell lung cancer who develop resistance to, or become intolerant of crizotinib.

September 11th 2021, 3:38pm

International Myeloma Society Annual Meeting

Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.

September 11th 2021, 2:43pm

American Urological Association Annual Meeting

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

September 11th 2021, 2:15pm

American Urological Association Annual Meeting

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

September 11th 2021, 12:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

September 11th 2021, 12:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

September 10th 2021, 9:23pm

International Myeloma Society Annual Meeting

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

September 10th 2021, 9:15pm

American Urological Association Annual Meeting

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.

September 10th 2021, 9:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

September 10th 2021, 8:53pm

American Urological Association Annual Meeting

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

September 10th 2021, 8:48pm

American Urological Association Annual Meeting

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec for the treatment of patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

September 10th 2021, 8:31pm

IASLC World Conference on Lung Cancer

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

September 10th 2021, 8:29pm

International Myeloma Society Annual Meeting

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

September 10th 2021, 8:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

September 10th 2021, 7:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

September 10th 2021, 6:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

September 10th 2021, 6:53pm

International Myeloma Society Annual Meeting

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

September 10th 2021, 6:31pm

International Myeloma Society Annual Meeting

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.